CO2019010943A2 - Anticuerpos de unión a vista a ph ácido - Google Patents
Anticuerpos de unión a vista a ph ácidoInfo
- Publication number
- CO2019010943A2 CO2019010943A2 CONC2019/0010943A CO2019010943A CO2019010943A2 CO 2019010943 A2 CO2019010943 A2 CO 2019010943A2 CO 2019010943 A CO2019010943 A CO 2019010943A CO 2019010943 A2 CO2019010943 A2 CO 2019010943A2
- Authority
- CO
- Colombia
- Prior art keywords
- sight
- acid
- binding antibodies
- antibodies
- acidic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se relaciona con anticuerpos que se unen específicamente al supresor de la activación de células T que contiene el dominio V de inmunoglobulina d(VISTA) a pH ácido y su uso en el tratamiento del cáncer. En algunas modalidades, los anticuerpos se unen específicamente a VISTA humano a pH ácido, pero no se unen significativamente a VISTA humano a pH neutro o fisiológico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471196P | 2017-03-14 | 2017-03-14 | |
US201862636746P | 2018-02-28 | 2018-02-28 | |
PCT/US2018/022230 WO2018169993A1 (en) | 2017-03-14 | 2018-03-13 | Antibodies binding to vista at acidic ph |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019010943A2 true CO2019010943A2 (es) | 2020-01-17 |
Family
ID=63522565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0010943A CO2019010943A2 (es) | 2017-03-14 | 2019-10-02 | Anticuerpos de unión a vista a ph ácido |
Country Status (16)
Country | Link |
---|---|
US (2) | US11603406B2 (es) |
EP (1) | EP3595720A4 (es) |
JP (2) | JP7211961B2 (es) |
KR (1) | KR20190128198A (es) |
CN (1) | CN110740749A (es) |
AU (1) | AU2018236218A1 (es) |
BR (1) | BR112019019108A2 (es) |
CA (1) | CA3054067A1 (es) |
CL (2) | CL2019002610A1 (es) |
CO (1) | CO2019010943A2 (es) |
IL (1) | IL269240A (es) |
MY (1) | MY200609A (es) |
PE (1) | PE20191708A1 (es) |
SG (1) | SG11201907848YA (es) |
TW (1) | TWI825010B (es) |
WO (1) | WO2018169993A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
CN107488228A (zh) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013081143A1 (ja) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬 |
KR20210084688A (ko) | 2012-08-24 | 2021-07-07 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
SI2970473T1 (sl) * | 2013-03-14 | 2017-10-30 | Bristol-Myers Squibb Company | Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe |
EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
EP3240804A4 (en) | 2014-12-19 | 2019-01-09 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE |
WO2016098356A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
CN111201038A (zh) | 2017-01-11 | 2020-05-26 | 戊瑞治疗有限公司 | Psgl-1拮抗剂及其用途 |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
KR20190128198A (ko) | 2017-03-14 | 2019-11-15 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
EP3630831B1 (en) | 2017-05-25 | 2022-06-15 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
CN111971304A (zh) * | 2018-03-21 | 2020-11-20 | 戊瑞治疗有限公司 | 在酸性pH结合至VISTA的抗体 |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
PE20210687A1 (es) * | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
WO2020016459A1 (en) * | 2018-07-20 | 2020-01-23 | Pierre Fabre Medicament | Receptor for vista |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
JP2022548292A (ja) * | 2019-09-19 | 2022-11-17 | ブリストル-マイヤーズ スクイブ カンパニー | 酸性pHでVISTAと結合する抗体 |
CA3226397A1 (en) | 2021-07-22 | 2023-01-26 | Ignacio Moraga GONZALEZ | Therapeutic muteins |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5605821A (en) | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
ES2183851T3 (es) | 1990-07-17 | 2003-04-01 | Univ Oklahoma | Ligando de gmp-140. |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
DK1396542T3 (da) | 1992-10-23 | 2011-06-06 | Genetics Inst Llc | P-selectin ligand protein |
EP0668907A1 (en) | 1992-11-16 | 1995-08-30 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for p-selectin and methods of use thereof |
AU2361395A (en) | 1994-04-28 | 1995-11-29 | Genetics Institute Inc. | Novel P-selectin ligand protein |
ES2208759T3 (es) | 1995-08-03 | 2004-06-16 | Board Of Regents Of The University Of Oklahoma | O-glicanos inhibidores de la inflamacion mediada por selectina. |
CA2230557A1 (en) | 1995-09-01 | 1997-03-13 | University Of Washington | Interactive molecular conjugates |
WO1999031117A1 (en) | 1997-12-18 | 1999-06-24 | Human Genome Sciences, Inc. | 110 human secreted proteins |
CA2331386A1 (en) | 1998-06-26 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
CA2339043A1 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU5249700A (en) | 1999-07-08 | 2001-01-30 | Protegene Inc. | Human proteins having hydrophobic domains and dnas encoding these proteins |
CA2404310A1 (en) | 2000-03-24 | 2001-10-04 | Meike Lorenz | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
EP1511861A4 (en) | 2002-06-12 | 2007-12-05 | Genencor Int | METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET |
WO2004022594A2 (en) | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
AU2005244081B2 (en) | 2004-05-11 | 2011-10-06 | Abgenomics Cooperatief U.A. | T-cell death-inducing epitopes |
CA2572239C (en) | 2004-06-24 | 2019-07-09 | Mayo Foundation For Medical Education And Research | B7-h5, a costimulatory polypeptide |
WO2006116181A2 (en) | 2005-04-25 | 2006-11-02 | Trustees Of Dartmouth College | Regulatory t cell mediator proteins and uses thereof |
WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
WO2007067984A2 (en) | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
EP2086998B1 (en) * | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
JP2011524858A (ja) | 2008-05-15 | 2011-09-08 | セレクシーズ ファーマスーティカルズ コーポレーション | 抗psgl−1抗体並びにその同定及び使用方法 |
US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
WO2010104821A1 (en) | 2009-03-09 | 2010-09-16 | Bioatla, Llc | Mirac proteins |
JP6034283B2 (ja) * | 2010-03-26 | 2016-11-30 | トラスティーズ・オブ・ダートマス・カレッジ | Vista制御性t細胞メディエータタンパク質、vista結合剤、およびその使用 |
CN103201293B (zh) | 2010-09-08 | 2016-04-27 | 哈洛齐梅公司 | 评估和鉴定或发展条件活性治疗蛋白的方法 |
US20130209449A9 (en) | 2011-06-13 | 2013-08-15 | Abgenomics Cooperatief U.A. | Anti-psgl-1 antibodies and uses thereof |
AU2012327211C9 (en) * | 2011-10-28 | 2016-11-17 | Biogen International Neuroscience Gmbh | TDP-43 specific binding molecules |
JP6181066B2 (ja) | 2011-11-28 | 2017-08-16 | ショー,グレイ,ディー. | 新規な増強型セレクチンアンタゴニスト |
NZ630020A (en) | 2012-03-08 | 2016-08-26 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2014039983A1 (en) * | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
JP6285923B2 (ja) | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用 |
US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2015109340A2 (en) | 2014-01-14 | 2015-07-23 | Noelle Randolph J | Vista antagonist and methods of use |
JP6682426B2 (ja) | 2013-05-24 | 2020-04-15 | メディミューン,エルエルシー | 抗b7−h5抗体およびその使用 |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ, インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
WO2015097536A2 (en) * | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
WO2015187359A1 (en) | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
JP7240808B2 (ja) | 2014-07-08 | 2023-03-16 | サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート | Psgl-1モジュレーターおよびその使用 |
JOP20150008B1 (ar) * | 2014-11-26 | 2021-08-17 | Janssen Pharmaceutica Nv | أجسام مضادة ل vista وأجزاء منها |
CN107405398A (zh) | 2014-12-05 | 2017-11-28 | 伊穆奈克斯特股份有限公司 | 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途 |
DK3229838T3 (da) | 2014-12-11 | 2020-10-19 | Pf Medicament | Anti-C10orf54-antistoffer og anvendelser deraf |
SG10202008304TA (en) * | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
EP3313882B1 (en) | 2015-06-24 | 2020-03-11 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
EP3371349A1 (en) | 2015-11-02 | 2018-09-12 | Bioatla, LLC | Conditionally active polypeptides |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
MX2018009800A (es) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos. |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
JP7184751B2 (ja) * | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | 抗ヒトvista抗体およびその使用 |
WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
EP3494141A4 (en) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY |
WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
CN111201038A (zh) | 2017-01-11 | 2020-05-26 | 戊瑞治疗有限公司 | Psgl-1拮抗剂及其用途 |
KR20190128198A (ko) | 2017-03-14 | 2019-11-15 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
EP3642231A4 (en) | 2017-06-22 | 2021-06-23 | Apexigen, Inc. | ANTI-VISTA ANTIBODIES AND METHODS OF USE |
MX2020005495A (es) | 2017-10-20 | 2021-01-08 | Pharmabcine Inc | Anticuerpo anti-vista y uso del mismo. |
CN111386128A (zh) | 2017-11-06 | 2020-07-07 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的联合疗法 |
US20210085785A1 (en) | 2018-02-23 | 2021-03-25 | Truebinding, Inc. | Treating cancer by blocking the interaction of vista and its binding partner |
CN111971304A (zh) | 2018-03-21 | 2020-11-20 | 戊瑞治疗有限公司 | 在酸性pH结合至VISTA的抗体 |
WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
PE20210687A1 (es) | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
CN109878421B (zh) | 2019-03-13 | 2020-11-03 | 浙江吉利控股集团有限公司 | 车辆坡道装置及汽车 |
CN110563843A (zh) | 2019-07-25 | 2019-12-13 | 钟小泉 | 一种靶向人vista蛋白的单克隆抗体 |
-
2018
- 2018-03-13 KR KR1020197029923A patent/KR20190128198A/ko not_active Application Discontinuation
- 2018-03-13 AU AU2018236218A patent/AU2018236218A1/en active Pending
- 2018-03-13 WO PCT/US2018/022230 patent/WO2018169993A1/en unknown
- 2018-03-13 PE PE2019001859A patent/PE20191708A1/es unknown
- 2018-03-13 JP JP2019549389A patent/JP7211961B2/ja active Active
- 2018-03-13 MY MYPI2019004903A patent/MY200609A/en unknown
- 2018-03-13 CA CA3054067A patent/CA3054067A1/en active Pending
- 2018-03-13 CN CN201880031212.2A patent/CN110740749A/zh active Pending
- 2018-03-13 BR BR112019019108A patent/BR112019019108A2/pt unknown
- 2018-03-13 EP EP18767615.0A patent/EP3595720A4/en active Pending
- 2018-03-13 SG SG11201907848YA patent/SG11201907848YA/en unknown
- 2018-03-13 US US16/493,712 patent/US11603406B2/en active Active
- 2018-03-14 TW TW107108715A patent/TWI825010B/zh active
-
2019
- 2019-09-10 IL IL26924019A patent/IL269240A/en unknown
- 2019-09-12 CL CL2019002610A patent/CL2019002610A1/es unknown
- 2019-10-02 CO CONC2019/0010943A patent/CO2019010943A2/es unknown
-
2021
- 2021-10-21 CL CL2021002769A patent/CL2021002769A1/es unknown
-
2023
- 2023-01-12 JP JP2023002879A patent/JP2023061927A/ja active Pending
- 2023-02-01 US US18/162,991 patent/US20240092907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20191708A1 (es) | 2019-11-28 |
AU2018236218A1 (en) | 2019-09-12 |
TWI825010B (zh) | 2023-12-11 |
JP7211961B2 (ja) | 2023-01-24 |
BR112019019108A2 (pt) | 2020-04-22 |
EP3595720A4 (en) | 2021-05-26 |
CL2021002769A1 (es) | 2022-08-12 |
WO2018169993A1 (en) | 2018-09-20 |
US20200055936A1 (en) | 2020-02-20 |
JP2020509756A (ja) | 2020-04-02 |
US20240092907A1 (en) | 2024-03-21 |
US11603406B2 (en) | 2023-03-14 |
CA3054067A1 (en) | 2018-09-20 |
CL2019002610A1 (es) | 2019-11-29 |
CN110740749A (zh) | 2020-01-31 |
IL269240A (en) | 2019-11-28 |
KR20190128198A (ko) | 2019-11-15 |
EP3595720A1 (en) | 2020-01-22 |
SG11201907848YA (en) | 2019-09-27 |
JP2023061927A (ja) | 2023-05-02 |
TW201843171A (zh) | 2018-12-16 |
MY200609A (en) | 2024-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019010943A2 (es) | Anticuerpos de unión a vista a ph ácido | |
CO2020012415A2 (es) | Anticuerpos de unión a vista a ph ácido | |
CL2023002543A1 (es) | Anticuerpos de unión a vista a ph ácido | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
CL2019003266A1 (es) | Anticuerpos anti-sirpalfa. | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
CO2022014820A2 (es) | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2) | |
UY38266A (es) | Piridinil y pirazinil-(aza) indolsulfonamidas | |
UY35620A (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
CO2023008643A2 (es) | Anticuerpos anti-hla-g y uso de estos | |
CO2022002937A2 (es) | Anticuerpos de unión a vista a ph ácido | |
AR115001A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
AR115729A1 (es) | ANTICUERPOS DE UNIÓN A VISTA EN pH ÁCIDO | |
AR120024A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
AR111180A1 (es) | ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO | |
CL2022002288A1 (es) | Anticuerpos de unión a vista a ph ácido (divisional solicitud 202002410) | |
EA201992139A1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH | |
EA202092208A1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH | |
EA202092495A1 (ru) | МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |